Tourbillon Capital Partners’s Amicus Therapeutics FOLD Stock Holding History

Tourbillon Capital Partners’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,414,130	Closed	-$17.1M	–	8
2018 Q3	$17.1M	Sell	1,414,130 -682,800	-33%	-$9.55M	1.84%	19
2018 Q2	$32.8M	Sell	2,096,930 -581,370	-22%	-$8.79M	1.27%	28
2018 Q1	$40.3M	Sell	2,678,300 -610,000	-19%	-$9.28M	1.6%	22
2017 Q4	$47.3M	Buy	3,288,300 +250,000	+8%	+$3.43M	1.75%	19
2017 Q3	$45.8M	Buy	3,038,300 +1,947,600	+179%	+$25.8M	1.11%	26
2017 Q2	$11M	Buy	+1,090,700	New	+$8.78M	0.21%	62
2015 Q4	–	Sell	-250,000	Closed	-$3.5M	–	82
2015 Q3	$3.5M	Buy	+250,000	New	+$3.92M	0.09%	87
2015 Q1	–	Sell	-500,000	Closed	-$4.16M	–	82
2014 Q4	$4.16M	Buy	+500,000	New	+$3.43M	0.11%	86

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Tourbillon Capital Partners's FOLD Position: Q4 2018 in Review

Tourbillon Capital Partners sold out of Amicus Therapeutics (FOLD) in Q4 2018, closing a stake of 1,414,130 shares — an estimated $17.1M sold.

Tourbillon Capital Partners first reported a position in FOLD in Q4 2014 and held it in 8 quarters. The position peaked at $47.3M in Q4 2017. 195 funds tracked by Wall St. Rank hold FOLD as of Q4 2018.

Tourbillon Capital Partners reported no remaining Amicus Therapeutics position as of Q4 2018 after selling out during the quarter.
Tourbillon Capital Partners sold 1,414,130 Amicus Therapeutics shares in Q4 2018, an estimated $17.1M.
Tourbillon Capital Partners first reported a position in Amicus Therapeutics in Q4 2014 and held it in 8 quarters.
Tourbillon Capital Partners's Amicus Therapeutics position peaked at $47.3M in Q4 2017.
195 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2018.

Based on Tourbillon Capital Partners's 13F filing for Q4 2018, filed 14 Feb 2019.